clinical trial · NCT07114861
The KN510713 Study in Combination With mFOLFIRINOX
New Cancer Cure-Bio Co.,Ltd.·phase2·recruiting·n = 30
Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOXStudy drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX
brief summary
This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).
started
Dec 16, 2025
primary completion
Sep 22, 2028
completion
Oct 22, 2028
last updated
Apr 13, 2026
official title
An Open-label, Dose-finding and Dose-expansion, Phase I/IIa Clinical Trial to Evaluate the Safety and Efficacy of KN510713 in Combination With mFOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol